In the final lecture of the session, Dr Enriqueta Felip (Vall d’Hebron University Hospital, Spain) discussed predictive biomarkers for immunotherapy in stage 4 NSCLC. The most extensively studied predictive diagnostics include PD-L1 immunohistochemistry, tumour inflammation including RNA immune signatures and tumour-infiltrating lymphocytes (TILs), tumour mutational burden (TMB), and oncogenic alterations like KRAS, STK11/LKB1, and EGFR.
PD-L1 expression is a biological continuum, so it is difficult to determine specific cut-off values. The magnitude of the benefit correlates with PD-L1 expression in the second-line treatment of NSCLC. However, some PD-L1-negative patients do respond to immunotherapy . Next, a growing body of evidence suggests that TMB is predictive of immunotherapy efficacy in NSCLC. However, there are multiple relevant challenges, such as the methodology, standardisation, definition of high vs low TMB, clini...
please login to read the entire article:
You need to register to read the entire article, please do so now.
Table of Contents: ELCC 2019
Current Management of Early Stage NSCLC
Trial Data: Early Stage Lung Cancer
Immunotherapy in Stage 4 Lung Cancer
Trials: Immunotherapy in Stage 4 Lung Cancer
Implementation of Personalised Lung Cancer Care in Clinical Routine
Optimal Management of Brain Metastases in NSCLC
Small Cell Lung Cancer: New Targets
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.